The failure of anxiolytic therapies in early clinical trials: What needs to be done

Expert Opinion on Investigational Drugs

Volumn 24, Issue 4, 2015, Pages 543-556

  Stewart, Adam Michael ^a,b   Nguyen, Michael ^a,c   Poudel, Manoj K ^a   Warnick, Jason E ^b,d   Echevarria, David J ^b,e   Beaton, Elliott A ^b,f   Song, Cai ^g,h   Kalueff, Allan V ^a,b,g  

^a ZENEREI Institute   (United States)

^b International Stress and Behavior Society (ISBS)   (Ukraine)

^c University of Virginia   (United States)

^d ARKANSAS TECH UNIVERSITY   (United States)

^e UNIVERSITY OF SOUTHERN MISSISSIPPI   (United States)

^f UNIVERSITY OF NEW ORLEANS   (United States)

^g GUANGDONG OCEAN UNIVERSITY   (China)

^h DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Anxiolytic drug; Clinical trial; Experimental model; Model organism; Preclinical study

Indexed keywords

ANXIOLYTIC AGENT; BIOLOGICAL MARKER;

AGE; ANXIETY DISORDER; BEHAVIOR ASSESSMENT; BRAIN DEVELOPMENT; CLINICAL TRIAL (TOPIC); DIFFUSION TENSOR IMAGING; DRUG EFFICACY; DRUG RESEARCH; DRUG TREATMENT FAILURE; ENDOPHENOTYPE; GENETIC MODEL; HUMAN; INBRED STRAIN; MEDICAL SOCIETY; MENTAL TEST; NERVE CELL DIFFERENTIATION; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTBRED STRAIN; PSYCHOPHARMACOTHERAPY; REVIEW; SEX; ANIMAL; ANXIETY DISORDERS; DRUG DESIGN; DRUG SCREENING; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS;

EID: 84924795027     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1019063     Document Type: Review

References (102)

1. Newschaffer CJ, Croen LA, Daniels J, et al. The epidemiology of autism spectrum disorders. Annu Rev Public Health 2007;28:235-58
2. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62(6):617
3. Kogan MD, Blumberg SJ, Schieve LA, et al. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 2009;124(5):1395-403
4. American Psychiatric Association APA. Diagnostic and statistical manual of mental disorders, fifth edition. American Psychiatric Association, Washington DC, USA;2013
5. Williams K, Wheeler D, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2013(8):CD004677
6. Fatemi SH, Realmuto GM, Khan L, Thuras P. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 1998;28(4):303-7
7. Pace TW, Mletzko TC, Alagbe O, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 2006;163(9):1630-3
8. Nemeroff CB, Vale WW. The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry 2005;66:5
9. Kalueff AV, Wheaton M, Murphy DL. What's wrong with my mouse model?: advances and strategies in animal modeling of anxiety and depression. Behav Brain Res 2007;179(1):1-18
10. Cryan JF, Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005;4(9):775-90
11. Griebel G, Holmes A. 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov 2013;12(9):667-87
12. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006;7(2):137-51
13. Cachat JM, Canavello PR, Elegante MF, et al. Modeling stress and anxiety in zebrafish. Zebrafish models in neurobehavioral research. Springer, New York, USA; 2011. p. 73-88
14. Kalueff AV, Tuohimaa P. The Suok ("ropewalking") murine test of anxiety. Brain Res Brain Res Protoc 2005;14(2):87-99
15. Nguyen M, Poudel MK, Stewart AM, Kalueff AV. Skin too thin? The developing utility of zebrafish skin (neuro)pharmacology for CNS drug discovery research. Brain Res Bull 2013;98:145-54
16. Nguyen M, Yang E, Neelkantan N, et al. Developing 'integrative' zebrafish models of behavioral and metabolic disorders. Behav Brain Res 2013;256:172-87
17. Sackerman J, Donegan JJ, Cunningham CS, et al. Zebrafish behavior in novel environments: effects of acute exposure to anxiolytic compounds and choice of Danio rerio line. Int J Comp Psychol 2010; 23(1):43
18. Stewart AM, Nguyen M, Wong K, et al. Developing zebrafish models of autism spectrum disorder (ASD). Prog Neuropsychopharmacol Biol Psychiatry 2014;50:27-36
19. Belzung C, Dubreuil D. Naloxone potentiates the anxiolytic but not the amnestic action of chlordiazepoxide in C57BL/6 mice. Behav Pharmacol 1998;9(8):691-8
20. Belzung C, Le Guisquet AM, Crestani F. Flumazenil induces benzodiazepine partial agonist-like effects in BALB/c but not C57BL/6 mice. Psychopharmacology (Berl) 2000;148(1):24-32
21. Fonio E, Benjamini Y, Golani I. Short and long term measures of anxiety exhibit opposite results. PLoS One 2012;7(10):e48414
22. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160(4):636-45
23. Gould TD, Gottesman II. Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav 2006;5(2):113-19
24. Dulawa SC, Holick KA, Gundersen B, Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004;29(7):1321-30
25. Clayton JC, Collins FS. Policy: NIH to balance sex in cell and animal studies. Nature 2014;509:282-3
26. Crawley JN. Behavioral phenotyping strategies for mutant mice. Neuron 2008;57(6):809-18
27. Bailey KR, Rustay NR, Crawley JN. Behavioral phenotyping of transgenic and knockout mice: practical concerns and potential pitfalls. ILAR J 2006;47(2):124-31
28. Crawley JN. Behavioral phenotyping of rodents. Comp Med 2003;53(2):140-6
29. Kalueff AV, Stewart AM, Kyzar EJ, et al. Time to recognize zebrafish affective behavior. Behaviour 2012;149(10-12):10-12
30. Wurbel H. Behavioral phenotyping enhanced-beyond (environmental) standardization. Genes Brain Behav 2002;1(1):3-8
31. Wahlsten D, Metten P, Phillips TJ, et al. Different data from different labs: lessons from studies of gene-environment interaction. J Neurobiol 2003;54(1):283-311
32. Crabbe JC, Wahlsten D, Dudek BC. Genetics of mouse behavior: interactions with laboratory environment. Science 1999;284(5420):1670-2
33. Kalueff AV, Wheaton M, Murphy DL. What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. Behav Brain Res 2007;179(1):1-18
34. Kalueff AV, LaPorte JL, Murphy DL, Sufka K. Hybridizing behavioral models: a possible solution to some problems in neurophenotyping research? Prog Neuropsychopharmacol Biol Psychiatry 2008;32(5):1172-8
35. Grubb SC, Bult CJ, Bogue MA. Mouse phenome database. Nucleic Acids Res 2014;42(D1):D825-D34
36. Phillips ML, Vieta E. Identifying functional neuroimaging biomarkers of bipolar disorder: toward DSM-V. Schizophr Bull 2007;33(4):893-904
37. Schneider B, Prvulovic D. Novel biomarkers in major depression. Curr Opin Psychiatry 2013;26(1):47-53
38. Egan RJ, Bergner CL, Hart PC, et al. Understanding behavioral and physiological phenotypes of stress and anxiety in zebrafish. Behav Brain Res 2009;205(1):38-44
39. Cachat J, Stewart A, Grossman L, et al. Measuring behavioral and endocrine responses to novelty stress in adult zebrafish. Nat Protoc 2010;5(11):1786-99
40. Canavello PR, Cachat JM, Beeson E, et al. Measuring endocrine (cortisol) responses of zebrafish to stress. In: Kalueff AV, Cachat J, editors. Zebrafish neurobehavioral protocols. Humana Press; New York: 2010
41. Griffiths BB, Schoonheim PJ, Ziv L, et al. A zebrafish model of glucocorticoid resistance shows serotonergic modulation of the stress response. Front Behav Neurosci 2012;6:68
42. Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Ann Med 2003;35(1):2-11
43. Greene J, Banasr M, Lee B, et al. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 2009;34(11):2459-68
44. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000;157(5):683-94
45. Leonard BE, Myint A. The psychoneuroimmunology of depression. Hum Psychopharmacol 2009;24(3):165-75
46. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65(9):732-41
47. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58(5):445-52
48. Simon NM, McNamara K, Chow CW, et al. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol 2008;18(3):230-3
49. Ventriglia M, Zanardini R, Pedrini L, et al. VEGF serum levels in depressed patients during SSRI antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(1):146-9
50. Stein C, Caccamo M, Laird G, Leptin M. Conservation and divergence of gene families encoding components of innate immune response systems in zebrafish. Genome Biol 2007;8(11):R251
51. Song C, Li X, Leonard BE, Horrobin DF. Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. J Lipid Res 2003;44(10):1984-91
52. Song C, Phillips AG, Leonard B. Interleukin 1 beta enhances conditioned fear memory in rats: possible involvement of glucocorticoids. Eur J Neurosci 2003;18(7):1739-43
53. Song C, Horrobin DF, Leonard BE. The comparison of changes in behavior, neurochemistry, endocrine, and immune functions after different routes, doses and durations of administrations of IL-1beta in rats. Pharmacopsychiatry 2006;39(3):88-99
54. Song C, Halbreich U, Han C, et al. Imbalance between pro-and antiinflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 2009;42(5):182-8
55. Idoko OT, Owolabi OA, Odutola AA, et al. Lessons in participant retention in the course of a randomized controlled clinical trial. BMC Res Notes 2014;7(1):706
56. Boyer EW, Shannon M. The Serotonin Syndrome. N Engl J Med 2005;352(11):1112-20
57. Stewart AM, Cachat J, Gaikwad S, et al. Perspectives on experimental models of serotonin syndrome in zebrafish. Neurochem Int 2013;62(6):893-902
58. Stoll G, Pietilainen OP, Linder B, et al. Deletion of TOP3beta, a component of FMRP-containing mRNPs, contributes to neurodevelopmental disorders. Nat Neurosci 2013;16(9):1228-37
59. Cross-Disorder Group of the Psychiatric Genomics Consortium. Lee SH, Ripke S, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013;45(9):984-94
60. Kalueff AV, Stewart AM. Modeling neuropsychiatric spectra to empower translational biological psychiatry. Behav Brain Res 2015;276:1-7
61. Kalueff AV, Ren-Patterson RF, LaPorte JL, Murphy DL. Domain interplay concept in animal models of neuropsychiatric disorders: a new strategy for high-throughput neurophenotyping research. Behav Brain Res 2008;188(2):243-9
62. Kyzar E, Gaikwad S, Roth A, et al. Towards high-throughput phenotyping of complex patterned behaviors in rodents: focus on mouse self-grooming and its sequencing. Behav Brain Res 2011;225(2):426-31
63. Bergner CL, Smolinsky AN, Hart PC, et al. Mouse models for studying depression-like states and antidepressant drugs. Methods Mol Biol 2010;602:267-82
64. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull 2009;35(2):383-402
65. Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med 2005;67(1):1-8
66. Holmes EA, Craske MG, Graybiel AM. Psychological treatments: a call for mental-health science. Nature 2014;511(7509):287-9
67. Jesuthasan S. Fear, anxiety, and control in the zebrafish. Dev Neurobiol 2012;72(3):395-403
68. Canavello P, Cachat J, Beeson E, et al. Measuring endocrine (cortisol) responses of zebrafish to stress. In: Kalueff AV, Cachat JM, editors. Zebrafish neurobehavioral protocols. Humana Press; 2011. p. 135-42
69. Kalueff AV, Stewart AM, Gerlai R. Zebrafish as an emerging model for studying complex brain disorders. Trends Pharmacol Sci 2014;35(2):63-75
70. Kalueff AV, Stewart AM, Gottesman II. Rethinking CNS disorders: time for new drug targets? Trends Pharmacol Sci 2014;35(10):491-2
71. Skolnick P. Anxioselective anxiolytics: on a quest for the Holy Grail. Trends Pharmacol Sci 2012;33(11):611-20
72. Paus T, Keshavan M, Giedd JN. Why do many psychiatric disorders emerge during adolescence? Nat Rev Neurosci 2008;9(12):947-57
73. Marsh R, Gerber AJ, Peterson BS. Neuroimaging studies of normal brain development and their relevance for understanding childhood neuropsychiatric disorders. J Am Acad Child Adolesc Psychiatry 2008;47(11):1233-51
74. Jaffee SR, Moffitt TE, Caspi A, et al. Differences in early childhood risk factors for juvenile-onset and adult-onset depression. Arch Gen Psychiatry 2002;59(3):215
75. Mitchell NC, Gould GG, Smolik CM, et al. Antidepressant-like drug effects in juvenile and adolescent mice in the tail suspension test: relationship with hippocampal serotonin and norepinephrine transporter expression and function. Front Pharmacol 2013;4:131
76. George S, Xia T, Rallo R, et al. Use of a high-throughput screening approach coupled with in vivo zebrafish embryo screening to develop hazard ranking for engineered nanomaterials. ACS Nano 2011;5(3):1805-17
77. Markou A. Accruing preclinical evidence about metabotropic glutamate 5 receptor antagonists as treatments for drug dependence highlights the irreplaceable contributions of animal studies to the discovery of new medications for human disorders. Neuropsychopharmacology 2009;34(4):817
78. Blaser RE, Penalosa YM. Stimuli affecting zebrafish (Danio rerio) behavior in the light/dark preference test. Physiol Behav 2011;104(5):831-7
79. Cachat J, Stewart A, Utterback E, et al. Three-dimensional neurophenotyping of adult zebrafish behavior. PLoS One 2011;6(3):e17597
80. Tye KM, Deisseroth K. Optogenetic investigation of neural circuits underlying brain disease in animal models. Nat Rev Neurosci 2012;13(4):251-66
81. Yizhar O. Optogenetic insights into social behavior function. Biol Psychiatry 2012;71(12):1075-80
82. Haznedar MM, Buchsbaum MS, Wei T-C, et al. Limbic circuitry in patients with autism spectrum disorders studied with positron emission tomography and magnetic resonance imaging. Am J Psychiatry 2000;157(12):1994-2001
83. Sundaram SK, Kumar A, Makki MI, et al. Diffusion tensor imaging of frontal lobe in autism spectrum disorder. Cereb Cortex 2008;18(11):2659-65
84. Stewart A, Wu N, Cachat J, et al. Pharmacological modulation of anxietylike phenotypes in adult zebrafish behavioral models. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(6):1421-31
85. Saeys Y, Inza I, Larranaga P. A review of feature selection techniques in bioinformatics. Bioinformatics 2007;23(19):2507-17
86. Loscalzo J, Barabasi AL. Systems biology and the future of medicine. Wiley Interdiscip Rev Syst Biol Med 2011;3(6):619-27
87. Gerlai R. Phenomics: fiction or the future? Trends Neurosci 2002;25(10):506-9
88. Fonio E, Golani I, Benjamini Y. Measuring behavior of animal models: faults and remedies. Nat Methods 2012;9(12):1167-70
89. Lemieux GA, Keiser MJ, Sassano MF, et al. In silico molecular comparisons of C. elegans and mammalian pharmacology identify distinct targets that regulate feeding. PLoS Biol 2013;11(11):e1001712
90. Lotan A, Fenckova M, Bralten J, et al. Neuroinformatic analyses of common and distinct genetic components associated with major neuropsychiatric disorders. Front Neurosci 2014;8:331
91. McNaughton N, Zangrossi H Jr. Theoretical approaches to the modeling of anxiety in animals. In: Blanchard R, Blanchard DC, Griebel G, Nutt DJ, editors. Handbook of anxiety and fear. Academic Press; London: 2008
92. Belzung C, Lemoine M. Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression. Biol Mood Anxiety Disord 2011;1(1):9
93. Kas MJ, Krishnan V, Gould TD, et al. Advances in multidisciplinary and crossspecies approaches to examine the neurobiology of psychiatric disorders. Eur Neuropsychopharmacol 2011;21(7):532-44
94. de Mooij-van Malsen AJ, Pjetri E, Kas MJ. The genetic and epigenetic landscape for CNS drug discovery targeting cross-diagnostic behavioral domains. Eur J Pharmacol 2014. [Epub ahead of print]
95. van der Staay FJ, Arndt SS, Nordquist RE. Evaluation of animal models of neurobehavioral disorders. Behav Brain Funct 2009;5:11
96. Robinson PN, Webber C. Phenotype ontologies and cross-species analysis for translational research. PLoS Genet 2014;10(4):e1004268
97. Pecina M, Zubieta JK. Molecular mechanisms of placebo responses in humans. Mol Psychiatry 2014. [Epub ahead of print]
98. McClatchey WC, Mahady GB, Bennett BC, et al. Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources. Pharmacol Ther 2009;123(2):239-54
99. Maximino C, da Silva AW, Araujo J, et al. Fingerprinting of psychoactive drugs in zebrafish anxiety-like behaviors. PLoS One 2014;9(7):e103943
100. Rihel J, Prober DA, Arvanites A, et al. Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. Science 2010;327(5963):348-51
101. Kokel D, Rennekamp AJ, Shah AH, et al. Behavioral barcoding in the cloud: embracing data-intensive digital phenotyping in neuropharmacology. Trends Biotechnol 2012;30(8):421-5
102. Daskalakis NP, Cohen H, Cai G, et al. Expression profiling associates blood and brain glucocorticoid receptor signaling with trauma-related individual differences in both sexes. Proc Natl Acad Sci USA 2014;111(37):13529-34